Lipid lowering therapy in cardiovascular disease : From myth to molecular reality
Copyright © 2020. Published by Elsevier Inc..
Lipid-lowering therapy is one major cornerstone of medical treatment of cardiovascular disease in order to modulate atherosclerosis. Statins, ezetimibe and novel PCSK9-inhibitors are already recommended in current guidelines and were shown to improve lipid profiles and have positive effects on the rate of ischemic events and cardiovascular mortality. Recent studies suggest that the concept of "The lower the better" might be valid at least regarding low density lipoproteins. In addition, lowering lipoprotein (a) still displays a major challenge in lipid therapy. Furthermore, also lowering triglycerides seems to improve cardiovascular outcome. Regarding triglycerides, icosapent ethyl, a polyunsaturated fatty acid recently attracted attention showing cardiovascular risk reduction due to triglyceride lowering. Therefore, new therapeutic strategies and drug classes are eagerly awaited. Targeting LDL, bempedoic acid and the siRNA inclisiran provide promising results. Moreover, regarding TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering. At least, using antisense-oligonucleotides against ApoC-III and Lp(a) resulted in promising outcomes. In this review, current and future options for lipid management are presented depending on different drug classes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:213 |
|---|---|
| Enthalten in: |
Pharmacology & therapeutics - 213(2020) vom: 01. Sept., Seite 107592 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mourikis, Philipp [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ezetimibe |
|---|
| Anmerkungen: |
Date Completed 18.06.2021 Date Revised 18.06.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.pharmthera.2020.107592 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310721822 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310721822 | ||
| 003 | DE-627 | ||
| 005 | 20231225140713.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.pharmthera.2020.107592 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1035.xml |
| 035 | |a (DE-627)NLM310721822 | ||
| 035 | |a (NLM)32492513 | ||
| 035 | |a (PII)S0163-7258(20)30120-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mourikis, Philipp |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lipid lowering therapy in cardiovascular disease |b From myth to molecular reality |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.06.2021 | ||
| 500 | |a Date Revised 18.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Inc. | ||
| 520 | |a Lipid-lowering therapy is one major cornerstone of medical treatment of cardiovascular disease in order to modulate atherosclerosis. Statins, ezetimibe and novel PCSK9-inhibitors are already recommended in current guidelines and were shown to improve lipid profiles and have positive effects on the rate of ischemic events and cardiovascular mortality. Recent studies suggest that the concept of "The lower the better" might be valid at least regarding low density lipoproteins. In addition, lowering lipoprotein (a) still displays a major challenge in lipid therapy. Furthermore, also lowering triglycerides seems to improve cardiovascular outcome. Regarding triglycerides, icosapent ethyl, a polyunsaturated fatty acid recently attracted attention showing cardiovascular risk reduction due to triglyceride lowering. Therefore, new therapeutic strategies and drug classes are eagerly awaited. Targeting LDL, bempedoic acid and the siRNA inclisiran provide promising results. Moreover, regarding TG a monoclonal antibody called evinacumab and an antisense-oligonucleotide against ANGPTL3 showed effective TG-lowering. At least, using antisense-oligonucleotides against ApoC-III and Lp(a) resulted in promising outcomes. In this review, current and future options for lipid management are presented depending on different drug classes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ezetimibe | |
| 650 | 4 | |a LDL | |
| 650 | 4 | |a Lipids | |
| 650 | 4 | |a PCSK9i | |
| 650 | 4 | |a Statin | |
| 650 | 7 | |a Hypolipidemic Agents |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Zako, Saif |e verfasserin |4 aut | |
| 700 | 1 | |a Dannenberg, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nia, Amir M |e verfasserin |4 aut | |
| 700 | 1 | |a Heinen, Yvonne |e verfasserin |4 aut | |
| 700 | 1 | |a Busch, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Richter, Hannah |e verfasserin |4 aut | |
| 700 | 1 | |a Hohlfeld, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Zeus, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Kelm, Malte |e verfasserin |4 aut | |
| 700 | 1 | |a Polzin, Amin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacology & therapeutics |d 1981 |g 213(2020) vom: 01. Sept., Seite 107592 |w (DE-627)NLM000442402 |x 1879-016X |7 nnns |
| 773 | 1 | 8 | |g volume:213 |g year:2020 |g day:01 |g month:09 |g pages:107592 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.pharmthera.2020.107592 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 213 |j 2020 |b 01 |c 09 |h 107592 | ||